Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man.

Howden, Colin W.; Forrest, J. A. H.; Meredith, Peter A.; Reid, JL

doi:10.1111/j.1365-2125.1985.tb05044.x

Cited by 22 publications

(17 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was marked inter-individual variation in tmax, Cmax and AUC as was noted by Tuynman et al (1987) and by ourselves in previous studies (Howden et al, 1984(Howden et al, ,1985. In this study, we did not detect any significant alterations in tmax, Cmax or AUC for omeprazole when it was given with antacid or following metoclopramide.…”

supporting

confidence: 70%

The effect of antacids and metoclopramide on omeprazole absorption and disposition.

Howden

Reid

1988

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

supporting

confidence: 70%

The effect of antacids and metoclopramide on omeprazole absorption and disposition.

Howden

Reid

1988

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“… 11 Whilst the greater antisecretory effect of lansoprazole is not large enough to affect oesophagitis healing rates, it may accelerate symptom relief during the first few days of treatment. Omeprazole has relatively low bioavailability in the first few days of administration and may take up to 5 days to achieve a pharmacodynamic steady state 17 –20 . It then exerts enough antisecretory effect to maintain intragastric pH above 4 for a sufficient period of time to heal oesophageal erosions, just as effectively as lansoprazole 2 …”

Section: Discussionmentioning

confidence: 99%

Meta‐analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis

Sharma

Leontiadis

Howden

2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Proton pump inhibitors are the drugs of choice for the treatment of erosive oesophagitis. In comparative clinical trials and in meta-analyses, they have been shown to be superior to H 2 -receptor antagonists in healing oesophageal erosions and in relieving associated symptoms. 1 For the different classes of antisecretory drugs, there is a statistically signi®cant linear relationship between suppression of 24-h intragastric acidity and oesophagitis healing rates. 2 In one comparative pharmacodynamic study, lansoprazole 30 mg o.d. produced a quantitatively greater degree of suppression of intragastric acidity than omeprazole 20 mg. 3 These doses of the two drugs are typically used in the treatment of erosive oesophagitis. Through the metaanalysis of randomized controlled trials, we wanted to determine whether the putative superior antisecretory effect of lansoprazole had been translated into a demonstrable advantage in healing rates. MATERIALS AND METHODSUsing the MEDLINE and EMBASE databases, two of the authors independently performed fully recursive literature searches for randomized controlled trials comparing omeprazole and lansoprazole in erosive oesophagitis. We used`omeprazole',`lansoprazole', and`oesophagitis' as text words and key words in the SUMMARY Background: Omeprazole and lansoprazole are used to treat erosive oesophagitis in the respective daily doses of 20 and 30 mg. Aim: To investigate, by meta-analysis, whether treatment with lansoprazole 30 mg increases erosive oesophagitis healing rates over omeprazole 20 mg. Methods: We searched for randomized, double-blind trials comparing omeprazole 20 mg and lansoprazole 30 mg in endoscopically diagnosed erosive oesophagitis. After assessing for homogeneity, non-heterogeneous trials were combined and pooled healing rates derived. We calculated the relative bene®t increase, absolute bene®t increase and number needed to treat.

show abstract

“…13,43,44 Peak plasma concentrations and AUe increase significantly after five to seven days of treatment. Howden et al demonstrated mean increases in the AUe of 86 and 128 percent after seven days ofrepeated oral doses of 30 and 60 mg/d, respectively.…”

Section: Bsoryflonmentioning

confidence: 97%

Omeprazole: A Novel Antisecretory Agent for the Treatment of Acid-Peptic Disorders

Lampkin¹,

Ouellet²,

Hak³

et al. 1990

DICP

View full text Add to dashboard Cite

Omeprazole represents the first agent of a unique class of acid inhibitory drugs, the proton pump inhibitors. Omeprazole inhibits basal gastric acid secretion, as well as gastrin-, histamine-, or pentagastrin-stimulated secretion, which results in decreased gastric acidity, decreased gastric acid output, and decreased gastric volume. Omeprazole is acid labile, necessitating its oral administration in an enteric-coated formulation. Bioavailability appears to be dose-dependent, with more drug being absorbed with increasing dosage as well as after repeated dosing. This is probably secondary to decreased gastric acidity and, therefore, less degradation of the administered drug. Despite its relatively short half-life (1-2 h), omeprazole's pharmacologic action is prolonged. Clinical trials have shown omeprazole to be at least as effective as histamine2-receptor antagonists in the treatment of gastric ulcers, duodenal ulcers, gastroesophageal reflux, and Zollinger-Ellison syndrome. Adverse reactions have been minimal. Omeprazole has been approved by the Food and Drug Administration for short-term therapy of severe erosive esophagitis, poorly responsive symptomatic gastroesophageal reflux disease, and long-term management of Zollinger-Ellison syndrome.

show abstract

Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man.

Cited by 22 publications

References 7 publications

The effect of antacids and metoclopramide on omeprazole absorption and disposition.

The effect of antacids and metoclopramide on omeprazole absorption and disposition.

Meta‐analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis

Omeprazole: A Novel Antisecretory Agent for the Treatment of Acid-Peptic Disorders

Contact Info

Product

Resources

About